NCT00602407已完成不适用
A Single Dose, Randomized, Two-Period, Two-Treatment, Crossover Bioequivalency Study of Cilostazol 50 mg Tablets Under Fasting Conditions
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
The objective of this study was the bioequivalence of a Roxane Laboratories' Cilostazol Tablets, 50 mg, to PLETAL® Tablets, 50 mg (OTSUKA Pharmaceuticals) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, crossover design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening.
排除标准
- •Positive test for HIV, Hepatitis B, or Hepatitis C.
- •Treatment with known enzyme altering drugs.
- •History of allergic or adverse response to Cilostazol or any comparable or similar product.
结局指标
主要结局
Bioequivalence
时间窗: Baseline, Two period, Seven day washout
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting ConditionsIntermittent ClaudicationNCT00602173Roxane Laboratories32
已完成
1 期
Crossover Bioequivalence Study of Tinidazole 500 mg Tablets Under Fed ConditionsTrichomoniasisNCT01591889Roxane Laboratories28
已完成
不适用
Bioequivalency Study of Meloxicam Tablets Under Fasting ConditionsInflammationNCT00618163Roxane Laboratories47
已完成
不适用
Bioequivalency Study of Meloxicam Tablets Under Fed ConditionsInflammationNCT00601887Roxane Laboratories48
已完成
不适用
Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed ConditionsShort Term Treatment of InsomniaNCT00694317Roxane Laboratories40